Boston Scientific Raises Outlook on Continued Cardiovascular Growth

Dow Jones10-22

By Nicholas G. Miller

Boston Scientific recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.

The medical device company logged net income of $755 million, or 51 cents a share, up from $469 million, or 32 cents a share the year prior.

Adjusted earnings were 75 cents a share. Analysts had expected 71 cents, according to FactSet.

Sales rose 20% to $5.07 billion, beating Wall Street's forecast of $4.97 billion. Top-line gains were fueled by the company's cardiovascular segment, which saw 22% net sales growth in the quarter.

The company increased its full-year adjusted earnings guidance to $3.02 to $3.04 a share from its previous forecast of $2.95 to $2.99 a share. Analysts see full-year adjusted earnings of $2.98.

Boston Scientific also guided for fourth-quarter earnings of 77 cents to 79 cents a share. Analysts see 76 cents a share.

Truist analysts said in a note late last month that the company has a diverse and promising product pipeline, fueled by internal development and acquisitions, which should provide strong revenue growth in coming years.

Earlier this month, the company agreed to acquire the rest of Nalu Medical, a medical technology company focused on chronic pain, for $533 million to add to merger agreements earlier this year with SoniVie and Bolt Medical.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

October 22, 2025 06:45 ET (10:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577363814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577363814","market":"fut","top_or_hot":-1,"title":"Boston Scientific Raises Outlook on Continued Cardiovascular Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Boston Scientific recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment. \n</p>\n<p>\n  The medical device company logged net income of $755 million, or 51 cents a share, up from $469 million, or 32 cents a share the year prior. \n</p>\n<p>\n  Adjusted earnings were 75 cents a share. Analysts had expected 71 cents, according to FactSet. \n</p>\n<p>\n  Sales rose 20% to $5.07 billion, beating Wall Street's forecast of $4.97 billion. Top-line gains were fueled by the company's cardiovascular segment, which saw 22% net sales growth in the quarter. \n</p>\n<p>\n  The company increased its full-year adjusted earnings guidance to $3.02 to $3.04 a share from its previous forecast of $2.95 to $2.99 a share. Analysts see full-year adjusted earnings of $2.98. \n</p>\n<p>\n  Boston Scientific also guided for fourth-quarter earnings of 77 cents to 79 cents a share. Analysts see 76 cents a share. \n</p>\n<p>\n  Truist analysts said in a note late last month that the company has a diverse and promising product pipeline, fueled by internal development and acquisitions, which should provide strong revenue growth in coming years. \n</p>\n<p>\n  Earlier this month, the company agreed to acquire the rest of Nalu Medical, a medical technology company focused on chronic pain, for $533 million to add to merger agreements earlier this year with SoniVie and Bolt Medical. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 06:45 ET (10:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific Raises Outlook on Continued Cardiovascular Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific Raises Outlook on Continued Cardiovascular Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-22 18:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Boston Scientific recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment. \n</p>\n<p>\n  The medical device company logged net income of $755 million, or 51 cents a share, up from $469 million, or 32 cents a share the year prior. \n</p>\n<p>\n  Adjusted earnings were 75 cents a share. Analysts had expected 71 cents, according to FactSet. \n</p>\n<p>\n  Sales rose 20% to $5.07 billion, beating Wall Street's forecast of $4.97 billion. Top-line gains were fueled by the company's cardiovascular segment, which saw 22% net sales growth in the quarter. \n</p>\n<p>\n  The company increased its full-year adjusted earnings guidance to $3.02 to $3.04 a share from its previous forecast of $2.95 to $2.99 a share. Analysts see full-year adjusted earnings of $2.98. \n</p>\n<p>\n  Boston Scientific also guided for fourth-quarter earnings of 77 cents to 79 cents a share. Analysts see 76 cents a share. \n</p>\n<p>\n  Truist analysts said in a note late last month that the company has a diverse and promising product pipeline, fueled by internal development and acquisitions, which should provide strong revenue growth in coming years. \n</p>\n<p>\n  Earlier this month, the company agreed to acquire the rest of Nalu Medical, a medical technology company focused on chronic pain, for $533 million to add to merger agreements earlier this year with SoniVie and Bolt Medical. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 06:45 ET (10:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574055.USD","symbol_name":"富达全球健康医疗A ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577363814","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577363814","pubTimestamp":1761129900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Boston Scientific recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.The medical device company logged net income of $755 million, or 51 cents a share, up from $469 million, or 32 cents a share the year prior.Adjusted earnings were 75 cents a share. Analysts had expected 71 cents, according to FactSet.Sales rose 20% to $5.07 billion, beating Wall Street's forecast of $4.97 billion. Top-line gains were fueled by the company's cardiovascular segment, which saw 22% net sales growth in the quarter.The company increased its full-year adjusted earnings guidance to $3.02 to $3.04 a share from its previous forecast of $2.95 to $2.99 a share. Analysts see full-year adjusted earnings of $2.98.Boston Scientific also guided for fourth-quarter earnings of 77 cents to 79 cents a share. Analysts see 76 cents a share.Earlier this month, the company agreed to acquire the rest of Nalu Medical, a medical technology ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0882574055.USD":"富达全球健康医疗A ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4581":"高盛持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","CSII":"Cardiovascular Systems","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4082":"医疗保健设备","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4504":"桥水持仓","LU0238689110.USD":"贝莱德环球动力股票基金","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","BSX":"波士顿科学","BK4588":"碎股","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"波士顿科学公司上调心血管系统持续增长的前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5,"CSII":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Boston Scientific recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment. \n\n\n  The medical device company logged net income of $755 million, or 51 cents a share, up from $469 million, or 32 cents a share the year prior. \n\n\n  Adjusted earnings were 75 cents a share. Analysts had expected 71 cents, according to FactSet. \n\n\n  Sales rose 20% to $5.07 billion, beating Wall Street's forecast of $4.97 billion. Top-line gains were fueled by the company's cardiovascular segment, which saw 22% net sales growth in the quarter. \n\n\n  The company increased its full-year adjusted earnings guidance to $3.02 to $3.04 a share from its previous forecast of $2.95 to $2.99 a share. Analysts see full-year adjusted earnings of $2.98. \n\n\n  Boston Scientific also guided for fourth-quarter earnings of 77 cents to 79 cents a share. Analysts see 76 cents a share. \n\n\n  Truist analysts said in a note late last month that the company has a diverse and promising product pipeline, fueled by internal development and acquisitions, which should provide strong revenue growth in coming years. \n\n\n  Earlier this month, the company agreed to acquire the rest of Nalu Medical, a medical technology company focused on chronic pain, for $533 million to add to merger agreements earlier this year with SoniVie and Bolt Medical. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2025 06:45 ET (10:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577363814","isCrawlerRequest":true}